Paul gets triple-A rating on royalties fund
New York-based Paul Capital Partners has securitised most of the assets in a $300m drug-royalty fund.
12 January 2013•1 min read
New York-based Paul Capital Partners has securitised most of the assets in a $300m drug-royalty fund.
